🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Lupin Limited LUPIN NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.lupin.com
Company Profile ↓
₹2,494.30
+32.46% 1Y
Mkt Cap₹1.14 L Cr
P/E21.42
P/B5.07
Div. Yield0.72%
52W High₹2,503.30
52W Low₹1,851.80
Book Value₹491.02
EPS (TTM)₹116.44

Company Overview

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women's health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company has a strategic collaboration with TB Alliance for the development and commercialization of the investigational drug Telacebec for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 23.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 28.4%.

Consistent Profit Growth

Net profit has compounded at 131.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 19.1% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 21.4, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 19.4%.

Recent Developments

  • Mar 2026 Revenue of ₹27,487.54 Cr (+23.9% YoY); net profit ₹5,332.84 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +23.9%, earnings +62.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 19.1%, profit CAGR 131.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:19.10%
1 Year:23.86%

Compounded Profit Growth

5 Years:131.46%
1 Year:62.51%

Stock Price Performance

1 Year:+32.46%
6 Months:+13.98%
3 Months:+7.23%
1 Month:+9.50%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 99% of range
₹1,851.80 ₹2,503.30
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)65.87 · Neutral
Price Performance
1M+9.50%
3M+7.23%
6M+13.98%
1Y+32.46%
Valuation vs Sector

P/E of 21.42 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 23.8%.
  • Healthy ROCE of 28.4%.
  • Compounding revenue at 19.1% over 5 years.
  • Profit CAGR of 131.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
21.42
Industry PE
39.97
Forward P/E
24.38
PEG Ratio
-
Book Value
₹491.02
Price to Book
5.07
P/S
4.08
EV/EBITDA
13.65
Dividend Yield
0.72%

Growth (CAGR)

Revenue 5Y
19.10%
Profit 5Y
131.46%
Revenue (YoY)
23.86%
Earnings (YoY)
62.51%

Profitability & Returns

ROCE
28.42%
ROE
23.76%
ROA
13.90%
Profit Margin
19.40%
Op Margin
53.41%
Gross Margin
73.35%
EPS (Latest Qtr)
₹31.89
EPS (TTM)
₹116.44

Balance Sheet & Liquidity

Debt/Equity
0.29
Quick Ratio
1.42
Current Ratio
1.90
Debt
₹6,616.18 Cr
Total Assets
₹38,364.83 Cr
Current Assets
₹24,027.38 Cr
Working Capital
₹11,376.14 Cr

Ownership

Promoter Holding
47.02%
Chg in Prom Hold
0.17%
FII / Inst Holding
34.71%
Chg in FII Hold
0.11%

Financial Snapshot

Enterprise Value
₹1.14 L Cr
Total Revenue (TTM)
₹27,487.54 Cr
EBITDA
₹8,682.54 Cr
Free Cash Flow
₹5,279.65 Cr
Operating Cash Flow
₹7,334.50 Cr
Shares Outstanding
₹45.72 Cr
Gross Margin
73.35%
Payout Ratio
10.31%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,562.00 55.36 ₹1.06 L Cr 0.08% 13.75% 11.74% 17.73% 14.28%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 4,430.00 Cr4,814.00 Cr5,039.00 Cr5,197.00 Cr4,961.00 Cr5,600.00 Cr-5,618.56 Cr5,562.20 Cr6,163.75 Cr7,048.00 Cr7,100.45 Cr7,391.91 Cr
Cost of Revenue -------1,721.55 Cr1,686.20 Cr1,771.93 Cr-1,878.13 Cr1,851.63 Cr
Gross Profit -------3,897.01 Cr3,876.00 Cr4,391.82 Cr-5,222.32 Cr5,540.28 Cr
Operating Expenses 3,852.00 Cr3,958.00 Cr4,121.00 Cr4,159.00 Cr3,964.00 Cr4,359.00 Cr-2,802.61 Cr2,977.06 Cr1,163.86 Cr4,706.00 Cr3,325.79 Cr3,816.00 Cr
Operating Income 314.00 Cr621.00 Cr670.00 Cr781.00 Cr540.00 Cr993.00 Cr-1,094.40 Cr898.94 Cr3,227.96 Cr2,024.00 Cr1,896.53 Cr1,724.28 Cr
EBITDA 578.00 Cr856.00 Cr918.00 Cr1,038.00 Cr997.00 Cr1,241.00 Cr-1,409.61 Cr1,378.12 Cr1,692.75 Cr2,341.00 Cr1,949.98 Cr2,494.95 Cr
Interest Expense 93.00 Cr86.00 Cr81.00 Cr74.00 Cr71.00 Cr68.00 Cr-66.89 Cr89.10 Cr91.76 Cr108.00 Cr114.98 Cr120.16 Cr
Pretax Income 258.00 Cr559.00 Cr630.00 Cr736.00 Cr498.00 Cr993.00 Cr-1,071.27 Cr895.84 Cr1,415.54 Cr2,007.00 Cr1,522.04 Cr1,928.00 Cr
Tax Provision 15.48 Cr106.21 Cr132.30 Cr117.76 Cr129.48 Cr188.67 Cr-212.41 Cr113.46 Cr194.08 Cr521.82 Cr341.53 Cr459.33 Cr
Net Income 242.00 Cr453.00 Cr495.00 Cr619.00 Cr368.00 Cr806.00 Cr-855.16 Cr772.52 Cr1,219.03 Cr1,485.00 Cr1,175.55 Cr1,460.34 Cr
Diluted EPS 5.199.9410.7613.477.8917.58-18.6916.8726.6232.3625.6731.89

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 12,770.00 Cr14,256.00 Cr17,367.00 Cr15,797.00 Cr14,665.00 Cr15,375.00 Cr15,163.00 Cr-16,269.98 Cr19,656.34 Cr22,192.11 Cr27,487.54 Cr
Cost of Revenue --------7,264.89 Cr7,146.78 Cr6,842.25 Cr7,326.46 Cr
Gross Profit --------9,005.09 Cr12,509.56 Cr15,349.86 Cr20,161.08 Cr
Operating Expenses 9,146.00 Cr10,564.00 Cr12,865.00 Cr12,649.00 Cr12,104.00 Cr13,020.00 Cr12,596.00 Cr-8,115.65 Cr9,712.92 Cr11,241.60 Cr5,479.54 Cr
Operating Income 3,189.00 Cr3,204.00 Cr3,590.00 Cr2,062.00 Cr1,715.00 Cr1,385.00 Cr1,680.00 Cr-889.44 Cr2,796.64 Cr4,108.26 Cr14,681.54 Cr
EBITDA 3,624.00 Cr3,691.00 Cr4,502.00 Cr3,148.00 Cr2,561.00 Cr2,355.00 Cr2,567.00 Cr-1,837.39 Cr3,898.12 Cr5,479.13 Cr8,682.54 Cr
Interest Expense 10.00 Cr59.00 Cr153.00 Cr204.00 Cr302.00 Cr363.00 Cr141.00 Cr-240.21 Cr279.04 Cr294.87 Cr434.49 Cr
Pretax Income 3,415.00 Cr3,329.00 Cr3,543.00 Cr547.00 Cr1,503.00 Cr887.00 Cr1,676.00 Cr-716.49 Cr2,422.27 Cr4,015.00 Cr6,872.55 Cr
Tax Provision 956.20 Cr1,065.28 Cr992.04 Cr289.91 Cr886.77 Cr1,153.10 Cr452.52 Cr-268.80 Cr486.70 Cr708.74 Cr1,517.08 Cr
Net Income 2,444.00 Cr2,270.00 Cr2,565.00 Cr258.00 Cr615.00 Cr-270.00 Cr1,228.00 Cr-430.08 Cr1,914.48 Cr3,281.62 Cr5,332.84 Cr
Diluted EPS 53.4750.1756.635.5613.40-5.9526.81-9.4141.8771.69116.44

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 13,054.00 Cr22,298.00 Cr26,212.00 Cr26,020.00 Cr27,661.00 Cr24,810.00 Cr23,430.00 Cr-22,955.93 Cr23,997.18 Cr29,204.88 Cr38,364.83 Cr
Current Assets --------12,451.30 Cr13,447.65 Cr16,798.58 Cr24,027.38 Cr
Cash & Equivalents --------1,277.82 Cr1,187.60 Cr1,930.78 Cr4,167.73 Cr
Inventory --------4,491.76 Cr4,953.90 Cr5,476.35 Cr6,083.25 Cr
Receivables --------4,480.70 Cr4,692.05 Cr5,497.10 Cr6,604.06 Cr
Total Liabilities --------10,413.11 Cr9,623.73 Cr11,910.53 Cr15,851.46 Cr
Current Liabilities --------9,265.37 Cr8,501.50 Cr8,961.39 Cr12,651.24 Cr
Long Term Debt --------27.51 Cr01,766.23 Cr1,643.39 Cr
Total Debt 537.00 Cr7,178.00 Cr7,966.00 Cr7,143.00 Cr8,496.00 Cr6,305.00 Cr5,129.00 Cr-4,541.52 Cr2,921.77 Cr5,447.77 Cr6,616.18 Cr
Total Equity 8,874.00 Cr11,163.00 Cr13,497.00 Cr13,577.00 Cr13,742.00 Cr12,537.00 Cr13,803.00 Cr-12,464.50 Cr14,290.29 Cr17,203.50 Cr22,448.27 Cr
Shares Outstanding --------45.50 Cr45.57 Cr45.66 Cr45.72 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 2,733.00 Cr-382.00 Cr4,114.00 Cr1,751.00 Cr1,666.00 Cr1,469.00 Cr1,822.00 Cr-1,897.24 Cr3,648.36 Cr2,999.94 Cr7,334.50 Cr
Investing Cash Flow -1,034.00 Cr-6,769.00 Cr-2,527.00 Cr470.00 Cr-3,282.00 Cr1,107.00 Cr-1,240.00 Cr--1,286.77 Cr-1,712.20 Cr-4,171.89 Cr-3,864.59 Cr
Financing Cash Flow -197.00 Cr5,836.00 Cr433.00 Cr-1,492.00 Cr744.00 Cr-891.00 Cr-1,885.00 Cr--337.25 Cr-2,184.21 Cr1,731.88 Cr-845.87 Cr
Capital Expenditure -868.00 Cr-5,782.00 Cr-2,601.00 Cr-1,490.00 Cr-960.00 Cr-671.00 Cr-672.00 Cr--1,499.62 Cr-928.90 Cr-1,682.43 Cr-2,054.85 Cr
Free Cash Flow 1,865.00 Cr-6,164.00 Cr1,513.00 Cr261.00 Cr706.00 Cr798.00 Cr1,150.00 Cr-397.62 Cr2,719.46 Cr1,317.51 Cr5,279.65 Cr
Net Change in Cash 1,502.00 Cr-1,315.00 Cr2,019.00 Cr729.00 Cr-872.00 Cr1,685.00 Cr-1,303.00 Cr-273.22 Cr-248.05 Cr559.93 Cr2,624.04 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------55.3%63.6%69.2%73.3%
Operating Margin % 25.0%22.5%20.7%13.1%11.7%9.0%11.1%-5.5%14.2%18.5%53.4%
Net Margin % 19.1%15.9%14.8%1.6%4.2%-1.8%8.1%-2.6%9.7%14.8%19.4%
ROE % 27.5%20.3%19.0%1.9%4.5%-2.2%8.9%-3.5%13.4%19.1%23.8%
ROCE % --------6.5%18.0%20.3%57.1%

Shareholding Pattern

Insiders
47.02%
Institutions
34.71%
Public Float
65.52%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LUPIN

Google News Mon, 13 Jul 2026

Why You Might Be Interested In Lupin Limited (NSE:LUPIN) For Its Upcoming Dividend - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNRmhjd3A0TUVlUXhfWXV5R3ZySE9MR05teFRDNWVLM3V1bnY3bTJDWDFKWVhqbzlsSkFOS3Y5R0NWVkZKN0RwSXN3V0NpZUZ3TzdEM2RQdGQ2aTFCZ2JCRHJMR0NEbkttZ1k4dVJtUEhOaVdwNHpiSW9ZNFd1QlJSYmlZTUNycWdqc3BZcX…

Google News hu, 09 Jul 2026

Lupin stock steadies on US drug demand and pipeline strength - Ad-hoc-news.de

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPRWpQLUtTUUl6U2Zfb1VlYXM5ZW1lVzFpS0lpU1FqaFpOV3NZZGJEUUZvTEhmYThDRTJxU1M3RXJYQVQxT0I4ckotc1Vla3JDZVFSMXM5M1NyMndDQmNCa2pDcGUwVndkMzkyXzJoWjhWTVlVNkpURXp2TDZuVEdGRGxFbXVzQ0U5d0pzNz…

Google News Mon, 13 Jul 2026

Lupin FY26 report shows 51% renewable energy use - scanx.trade

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNbVgwTnEycVJLUlRHOVQxWHFZcktYNVA0QWtOcFZtcTFlWUZGZ0JZLTd5ejJRN3FnRm80eVlRZnkyc2hKSmxMU0Zpa1FLY3F3RzNlYVp2SkJtRnhyOGtRajNzTXIwX0NKQWVfeTNiekh5SzRCcVJCRmVVTWwwZzNtOGQ2Z20ydnpmZTE1cW…

Google News Mon, 29 Jun 2026

Lupin shares gain after USFDA grants tentative approval for Enzalutamide tablets - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOMFBwYlF6OWwxVUtvYWQwRDdJV19MUmJkOTdsd2lSdUY2aWpOZHNSSlpmTzNUTGhnRlpiQXFieUw1MU1aTHdFeU1LeTBCekRndk4zclNESEg4Y2E4SG5pUlE0NWl0SVRJTjJrOE5kMTJBdjFPdjZKby1EZEpTdUQzRjdvWVVrcjFfWVdoVE…

Google News Wed, 08 Jul 2026

Pharma stocks: Lupin, Torrent hit new peaks; Sun nears summit; here's why - Business Standard

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWVk0YVdKSGVub1dvbzc1TGRWenlmbWRwNWhNNDRCOGIwZVNkbnNyWmFBX2VQVDdmM2wwTU93b1ROVU5XcFdnaG1Kc0Q1aTJubXFXS3FsUGJDR2xaakhDOG1XVDE2c2lOem5YbThXX2NyNWdvdGZSM2FIMWgtQ2h0b0VzcmUycmhDclhIWE…

Google News Fri, 08 May 2026

Lupin Shares Slump Despite 90% Jump In Q4 Profit, Highest-Ever Dividend Announcement - NDTV Profit

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQX09MSXRLUWdzZy1DaFdHUGFzZzFlWDdfSl81SFBMbklQRUphTVJDOFdSMVVPSFREYzI5dVdITzJpZWZOY1pQRy1hX3YzczNvbHdxOC15RHhiZmpmTXUwZDkwc3RhUWtsY2pyNUFzZUtuTldRdGFhU0NRaWtnUlRPZkRlV3JyUFlwbnBkRG…

LUPIN — Frequently Asked Questions

What is the current share price of Lupin Limited (LUPIN)?

As of 2026-07-15 09:52 IST, Lupin Limited (LUPIN) trades at ₹2,494.30 on NSE. Its 52-week range is ₹1,851.80 to ₹2,503.30.

What is the market capitalisation of LUPIN?

Lupin Limited (LUPIN) has a market capitalisation of ₹1.14 L Cr on NSE.

What is the P/E ratio of LUPIN?

LUPIN trades at a trailing price-to-earnings (P/E) ratio of 21.42. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.07.

Does LUPIN pay a dividend?

Lupin Limited (LUPIN) currently offers a dividend yield of 0.72%.

What is the return on equity (ROE) of LUPIN?

LUPIN has a return on equity (ROE) of 23.76%. Its return on capital employed (ROCE) is 28.42%.

Is LUPIN a good stock to buy?

This page provides a data-driven analysis of Lupin Limited (LUPIN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space